-

AmerisourceBergen Announces Common Share Repurchase From Walgreens Boots Alliance

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $200 million in concurrence with Walgreens Boots Alliance’s sale of AmerisourceBergen shares pursuant to Rule 144.

AmerisourceBergen intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under AmerisourceBergen’s share repurchase program, and the repurchased shares will be held in treasury.

About AmerisourceBergen

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our approximately 44,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue.

Contacts

Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
610-727-3693
bmurphy@amerisourcebergen.com

Industry:

AmerisourceBergen Corporation

NYSE:ABC
Release Versions
English

Contacts

Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
610-727-3693
bmurphy@amerisourcebergen.com

More News From AmerisourceBergen Corporation

Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm. “We are excited to accelerate our acquisition of OneOncology, which will advance our management services...

Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for the September quarter of fiscal 2025, compared to $0.02 in the prior year quarter. Adjusted diluted EPS, which is a...

Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President &...
Back to Newsroom